4538 — Fuso Pharmaceutical Industries Income Statement
0.000.00%
Last trade - 00:00
- ¥19bn
- ¥26bn
- ¥51bn
- 27
- 86
- 49
- 55
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 46,074 | 46,901 | 49,251 | 49,632 | 51,015 |
Cost of Revenue | |||||
Gross Profit | 13,430 | 12,800 | 14,109 | 13,397 | 13,740 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 44,833 | 45,953 | 46,911 | 47,793 | 48,819 |
Operating Profit | 1,241 | 948 | 2,340 | 1,839 | 2,196 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,255 | 1,042 | 2,345 | 1,911 | 2,205 |
Provision for Income Taxes | |||||
Net Income After Taxes | 894 | 707 | 1,608 | 1,484 | 1,606 |
Net Income Before Extraordinary Items | |||||
Net Income | 894 | 707 | 1,608 | 1,484 | 1,606 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 894 | 707 | 1,607 | 1,483 | 1,605 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 104 | 82.4 | 177 | 177 | 184 |
Dividends per Share |